Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2017
December 2017, Vol 8, No 5
December 2017, Vol 8, No 5
Identifying Long-Term Unmet Needs in Survivorship Care
By
Meg Barbor, MPH
Survivorship
,
Policies & Guidelines
December 2017, Vol 8, No 5
New Orleans, LA—The number of cancer survivors is increasing. To keep up with this trend, survivorship care must evolve and become more efficient, insists Jennifer R. Klemp, PhD, MPH, MA, Director, Cancer Survivorship, University of Kansas Cancer Center, Westwood. A growing number of patients are living with or through their disease, while the provider workforce is shrinking.
Read Article
Clinical Pathways Help Integrate New Drugs, Reduce Variability in Care Delivery
By
Charles Bankhead
Clinical Pathways
December 2017, Vol 8, No 5
Chicago, IL—Clinical pathways have an important role in the integration of new cancer drugs into clinical practice. Between January 2015 and mid-2017, the FDA granted more than 60 new approvals in oncology, with new drugs accounting for the vast majority (as opposed to new indications). Staying abreast of new drugs and new indications for specific types of cancer requires much time, which presents an extra burden on community oncologists.
Read Article
Rapid Adoption of Oncology Drugs Improves Survival
By
Chase Doyle
Value in Oncology
December 2017, Vol 8, No 5
Innovation takes time, especially when it comes to cancer research. However, delays in the adoption of novel oncology treatments can have a significant impact on patient health, reported Jason Shafrin, PhD, Director of Healthcare Quality and Value-Based Research Methods, and Senior Research Economist, Precision Health Economics, Los Angeles, CA, who presented the results of a geographic-based analysis of claims data at the 2017 Cancer Survivorship Symposium.
Read Article
Identifying Correct Molecular Target Essential for Treating Non–Small-Cell Lung Cancer
By
Wayne Kuznar
Value in Oncology
December 2017, Vol 8, No 5
Orlando, FL—Non–small-cell lung cancer (NSCLC) comprises several different subtypes, necessitating broad molecular panel testing to understand the correct diagnosis and the appropriate treatment, said Wallace Akerley, MD, Senior Director, Community Oncology Research, Huntsman Cancer Institute, University of Utah, Salt Lake City, at the 2017 National Comprehensive Cancer Network (NCCN) annual conference.
Read Article
Taselisib, a PI3K Inhibitor, Shrinks Tumors in Early Breast Cancer, with Added Activity in Patients with PI3KCA Mutation
By
Phoebe Starr
ESMO 2017 Highlights
,
ESMO
December 2017, Vol 8, No 5
For the first time, a randomized clinical trial has shown significant tumor shrinkage with a phosphoinositide-3-kinase (PI3K) inhibitor in patients with estrogen receptor (ER)-positive, HER2-negative early breast cancer. The phase 3 study LORELEI compared neoadjuvant therapy with letrozole plus placebo versus letrozole plus taselisib, a PI3K inhibitor, in this patient population.
Read Article
Rucaparib Maintenance Extends Survival
By
Phoebe Starr
ESMO 2017 Highlights
,
ESMO
December 2017, Vol 8, No 5
Madrid, Spain—Maintenance therapy with the poly ADP-ribose polymerase (PARP) inhibitor rucaparib (Rubraca) after response to platinum-containing therapy significantly improved progression-free survival (PFS) by 11.2 months in patients with recurrent ovarian cancer compared with placebo, according to overall results of the ARIEL3 trial. The study was presented at the 2017 European Society for Medical Oncology (ESMO) Congress.
Read Article
Potentially Practice-Changing Results: PD-L1 Inhibitor for Unresectable, Stage III Lung Cancer
By
Phoebe Starr
ESMO 2017 Highlights
,
ESMO
December 2017, Vol 8, No 5
Madrid, Spain—Durvalumab (Imfinzi), a PD-L1 inhibitor, improved progression-free survival (PFS) by 11.2 months compared with placebo in patients with locally advanced, unresectable stage III non–small-cell lung cancer (NSCLC) that did not progress after standard treatment with chemoradiotherapy. These results—presented at the 2017 European Society for Medical Oncology (ESMO) Congress—come from PACIFIC, the first phase 3 clinical trial of a PD-L1 inhibitor in patients with locally advanced NSCLC outside of the metastatic setting.
Read Article
Community Oncology Is Key in Ensuring Access to Cancer Care
By
Wayne Kuznar
AVBCC Special Feature
December 2017, Vol 8, No 5
Community oncology has an important role in eliminating barriers to accessing healthcare and reducing disparities in cancer care. Improving access to high-quality, cost-effective cancer care was addressed from a variety of perspectives at the 2017 Association for Value-Based Cancer Care Summit.
Read Article
Big Data in Cancer Research and Precision Medicine
By
Wayne Kuznar
AVBCC Special Feature
December 2017, Vol 8, No 5
Read Article
Online First
Opdivo First Immunotherapy Approved for Hepatocellular Carcinoma
FDA Approvals, News & Updates
December 2017, Vol 8, No 5
On
September 22, 2017
, the FDA granted accelerated approval to nivolumab (Opdivo; Bristol-Myers Squibb) for the treatment of hepatocellular carcinoma (HCC)—the most common type of liver cancer—in patients who previously received sorafenib treatment. Opdivo received priority review for this indication.
Read Article
Page 2 of 2
1
2
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma